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OBJECTIVEdThe study objective was to evaluate the cost-effectiveness of alternative fasting
plasma glucose (FPG) thresholds to identify adults at high risk for type 2 diabetes for diabetes
preventive intervention.
RESEARCH DESIGN ANDMETHODSdWe used a validated simulation model to ex-
amine the change in lifetime quality-adjusted life years (QALYs) and medical costs when the FPG
threshold was progressively lowered in 5-mg/dL decrements from 120 to 90 mg/dL. The study
sample includes nondiabetic adults aged $45 years in the United States using 2006–2010 data
from the National Health and Nutrition Examination Survey. High-risk individuals were as-
sumed to receive a lifestyle intervention, as that used in the Diabetes Prevention Program. We
calculated cost per QALY by dividing the incremental cost by incremental QALY when lowering
the threshold to the next consecutive level. Medical costs were assessed from a health care system
perspective. We conducted univariate and probabilistic sensitivity analyses to assess the robust-
ness of the results using different simulation scenarios and parameters.
RESULTSdProgressively lowering the FPG threshold would monotonically increase QALYs,
cost, and cost per QALY. Reducing (in 5-mg/dL decrements) the threshold from 120 to 90mg/dL
cost $30,100, $32,900, $42,300, $60,700, $81,800, and $115,800 per QALY gained, respec-
tively. The costs per QALY gained were lower for all thresholds under a lower-cost and less-
effective intervention scenario.
CONCLUSIONSdLowering the FPG threshold leads to a greater health beneﬁt of diabetes
prevention but reduces the cost-effectiveness. Using the conventional benchmark of $50,000 per
QALY, a threshold of 105 mg/dL or higher would be cost effective. A lower threshold could be
selected if the intervention cost could be lowered.
Diabetes Care 36:3992–3998, 2013
Impaired fasting glucose (IFG) is anintermediate state of hyperglycemia inwhich fasting plasma glucose (FPG)
levels do not meet the criteria for diabetes
but are consistently elevated above what
is considered normal (1). The concept of
IFG has been endorsed by leading profes-
sional organizations (2,3) and adopted as
one measure for identifying the high-risk
population for type 2 diabetes preventive
interventions in clinical settings and
large-scale, community-based prevention
programs (4,5).
Despite the increasing use of FPG
testing to identify the high-risk state, the
appropriate threshold for the lower limit
of IFG remains unclear. The American
Diabetes Association (ADA) currently uses
100 mg/dL (5.6 mmol/L) as the threshold
to deﬁne IFG (6), while the World Health
Organization and the European Diabetes
Epidemiology Group recommends using
110 mg/dL (6.1 mmol/L) (7). Varying
standards exist in large part because there
is no clear threshold at which an FPG value
can be associated with a sharp increase in
the risk of future diabetes and its compli-
cations (7–10). Recent ADA guidelines also
recommend glycated hemoglobin (A1C)
as a blood test to identify people at high
risk for type 2 diabetes and such a contin-
uous relationship with the incidence of di-
abetes and its complications also has been
observed for A1C (6).
When FPG is used to identify the
target population for type 2 diabetes pre-
vention, the choice of the IFG-deﬁning
FPG threshold ultimately affects the in-
tervention’s cost-effectiveness. A lower
FPG threshold would result in more peo-
ple being eligible for intervention, which
would likely lead to more cases of diabetes
being prevented or delayed. However, a
lower threshold might be less cost-effective
because it incurs costs for intervening in a
population with a lower risk of developing
type 2 diabetes. To better understand the
potential cost implications, major clinical
and public health organizations called for
systematic economic analyses of the FPG
thresholds (3). Our study sought to esti-
mate and compare the long-term cost-
effectiveness of alternative FPG thresholds
for identifying high-risk adults for in-
clusion in type 2 diabetes prevention
programs.
RESEARCH DESIGN AND
METHODSdUsing the model de-
scribed below, we simulated average life-
time costs and quality-adjusted life years
(QALYs) for U.S. adults aged $45 years
who had no diabetes at baseline under sce-
narios using alternative FPG thresholds.
For each scenario, the FPG threshold
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was lowered by 5 mg/dL from that in the
previous scenario. We calculated results
for seven scenarios with FPG thresholds
ranging from 120 to 90 mg/dL. Thresh-
olds ,90 mg/dL were not considered be-
cause such a standard would identify a
vast majority of the U.S. population as
high risk. Lifetime cost and QALY esti-
mates from each scenario were used to es-
timate the cost-effectiveness associated
with each threshold.
Simulation model
Our model is a validated Markov-based
model in which the progression of type 2
diabetes was simulated based on annual
transition probabilities from a person’s di-
agnosis to death. In the model, separate
modules simulated incidence of and pro-
gression through each of ﬁve types of
diabetes complication (nephropathy,
neuropathy, retinopathy, stroke, and cor-
onary heart diseases) that people with di-
abetes could possibly develop. Details of
the model appear in the Supplementary
Data. The model has been validated (11)
and used for assessing the long-term cost-
effectiveness of various interventions for
preventing type 2 diabetes and its compli-
cations (12–15).
A nationally representative sample of
nondiabetic U.S. adults aged $45 years,
based on the 2006–2010 data from the
National Health and Nutrition Examina-
tion Survey, was used for the simulations.
We did not include people younger than
45 years because data concerning diabetes
incidence by FPG level in this population
are limited and relatively few people are
diagnosed with type 2 diabetes before age
45 (16). We identiﬁed people with diabe-
tes by self-report or by test results: FPG
$126 mg/dL, 2-h glucose value $200
mg/dL, or A1C $6.5% (6).
For each decremental 5 mg/dL FPG
value (threshold i, e.g., threshold115) eval-
uated in our simulations, the nondiabetic
sample was divided into two groups:
those at high risk for type 2 diabetes
(threshold i , FPG , 126 mg/dL) and
those with “normal” FPG (FPG, thresh-
oldi). The population size, baseline charac-
teristics, and diabetes incidence rate in the
two groups were all dependent on the FPG
threshold selected (i.e., the value of i.)
Rates of diabetes incidence in both
the high-risk group and the normal FPG
group were estimated using data from the
Atherosclerosis Risk in Communities
(ARIC) study, a prospective study includ-
ing 15,792 adults aged 45 years or older
at baseline in 1987 to 1989 (17). In the
study, diabetes incidence was deﬁned by
subsequent plasma measurements (fast-
ing glucose $126 mg/dL or nonfasting
glucose $200 mg/dL), a self-reported di-
agnosis of diabetes, or use of antidiabetic
medications during 6 years of follow-up
(18). The estimates of annual risk for de-
veloping type 2 diabetes used in the sim-
ulation are presented in Table 1. We
found that increments in the level of
FPG were associated with a continuum
of increasing risk for diabetes, which is
consistent with previous studies (18–22).
In the model, disease progression
subsequent to a diagnosis of diabetes
was simulated based on data primarily
obtained from the UK Prospective Di-
abetes Study (UKPDS) (23). Risk of de-
veloping hypertension, hyperlipidemia,
coronary heart disease, or stroke, all of
which are associated with diabetes, before
the clinical diagnosis of diabetes also was
incorporated in the model (9,24–26).
Technical details are provided in the Sup-
plementary Data.
Diabetes prevention interventions
In the simulation, we assumed that 50%
of individuals identiﬁed as high risk
started the lifestyle intervention and
50% of those completed the program
(27,28). Attrition was assumed to occur
evenly through the years of participation.
After 1 year of the lifestyle intervention,
participants received a test for diabetes.
The intervention and testing continued
annually until an individual was diag-
nosed with diabetes (by the deﬁnition of
diabetes used in the ARIC study), died, or
dropped out. The intervention was mod-
eled based on the intensive lifestyle inter-
vention program implemented in the
Diabetes Prevention Program (DPP) study
(4). The DPP study was a 3-year random-
ized trial with a 16-lesson core curriculum
covering diet, exercise, and behaviormod-
iﬁcation that was taught by case managers.
Lessons were delivered one-on-one for the
ﬁrst 6 months, followed by individual
and group sessions over the subsequent
6 months (4). The costs and effectiveness
measures associated with the intervention
are summarized in Table 2.
Among people who developed diabe-
tes while receiving intervention, we as-
sumed diabetes was diagnosed during the
year of onset. After diagnosis, these indi-
viduals would continue to receive the
lifestyle intervention and additionally
receive a metformin therapy (850 mg
twice per day) (29). This treatment would
last until the person’s A1C level reached
7.0%, at which point the person would
receive intensive treatment for glycemic
control, as implemented in the UKPDS
(15). Patients in the UKPDS were treated
intensively, with a goal of maintaining an
A1C level below 7.0% using metformin,
sulfonylureas, and dietary advice from a
dietitian.
The group with an FPG value below a
threshold (i.e., the low-risk group) was
assumed to receive no lifestyle interven-
tion. People in this group, as well as those
who were identiﬁed as high-risk individ-
uals but did not participate in the lifestyle
intervention, were assumed to develop
type 2 diabetes based on the incidence
rates observed in the ARIC study. When
their diabetes was clinically diagnosed,
the mean A1C level was assumed to be
7.1%, the level observed among UKPDS
subjects after the dietary run-in period
(23). After diagnosis, they were assumed
to receive the same intensive treatment for
glycemic control as those in the UKPDS.
Cost and health utility
The study was conducted from a health
care system perspective, and thus only the
following costs were considered: 1) the
cost of a one-time fasting glucose screen-
ing test for all participants; 2) the annual
cost for the lifestyle program and the
screening test for high-risk adults who
took up the intervention; and 3) treat-
ment costs for diabetes and diabetes-
related complications (details appear in
Supplementary Table 18). All costs are
expressed in 2012 U.S. dollars. Future
costs were discounted at 3% annually.
Calculations were performed in full pre-
cision and costs were rounded to the
nearest $100.
Table 1dAnnual risk of developing type 2
diabetes by FPG level
FPG level
(mg/dL)
Mean
follow-up
(years)
Annual risk
of developing
type 2 diabetes*
,90 9.97 0.006
90–,94 9.92 0.008
95–,99 9.99 0.012
100–,104 9.97 0.018
105–,109 9.98 0.031
110–,114 9.99 0.053
115–,119 9.95 0.080
120–,126 9.93 0.126
Data from the ARIC study. *The annual risks of
developing type 2 diabetes were calculated from
a 10-years survival function using the Kaplan-Meier
method.
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The health utility values of individu-
als with elevated FPG and type 2 diabetes
were based on data from the DPP study
(30) and a health utility model developed
byCoffey et al. (31), who estimated health
utility values associated with diabetes
treatment mode and diabetes-related com-
plications and adjusting for socioeconomic
and demographic variables. Their esti-
mated baseline utility score of 0.69 rep-
resents the utility value for a nonobese
man with type 2 diabetes who is treated
with diet and exercise, has no cardiovas-
cular risk factors, and has no microvas-
cular, neuropathic, or cardiovascular
complications. Additional treatments,
cardiovascular risk factors, or complica-
tions would lead to reductions from the
baseline utility score. Detailed speciﬁca-
tions on the health utilities appear in the
Supplementary Data (Supplementary
Table 19). QALYs were discounted at 3%
annually.
Incremental cost-effectiveness ratio
The cost-effectiveness associated with a
threshold was measured by the incremen-
tal cost-effectiveness ratio (ICER), which
was calculated by dividing the incremen-
tal cost by the incremental effectiveness
between that threshold (e.g.,115 mg/dL)
and its next higher threshold (e.g.,120
mg/dL) (32). This differs from conven-
tional cost-effectiveness analyses, in
which ICERs are calculated by comparing
cost and effectiveness of new interven-
tions with those of existing interventions
or with doing nothing. The objectives of
conventional analyses are to compare
cost-effectiveness of different intervention
options in a ﬁxed intervention population.
Conversely, the objective here was to assess
how the cost-effectiveness of a ﬁxed inter-
vention would change when the interven-
tion population (people with IFG) is
progressively expanded by lowering the
FPG value used to deﬁne IFG.
Sensitivity analyses
We conducted both univariate and prob-
abilistic sensitivity analyses. First we
tested whether using a different preven-
tive intervention might change the ICERs
of the FPG thresholds. We considered a
program implemented in the Promoting a
Lifestyle of Activity and Nutrition for
Working to Alter the Risk of Diabetes
(PLAN4WARD) study. PLAN4WARD is a
community-based program designed to
deliver at a lower cost the key elements of
the lifestyle intervention used in the DPP
study (33). Compared with the DPP
intervention, PLAN4WARD costs about
75% less and was 60% as effective in re-
ducing risk of diabetes (34). Details of the
cost and effectiveness of the intervention
appear in the Supplementary Data.
Second, data from the DPP study
suggest a greater reduction in diabetes
incidence in adults aged $60 years than
in those aged ,60 years (71% vs. 59%)
(4). To test the difference of the ICERs
among different age groups, we ran the
simulation for individuals aged 45–59
years and those aged $60 years, using
DPP estimates of effectiveness for the
two groups. In addition, we ran a separate
analysis for persons aged 18 to 44, as-
suming that, given the same FPG value,
they had the same level of risk of devel-
oping diabetes as persons aged 45 or
older.
We performed four additional uni-
variate sensitivity analyses to address un-
certainty associated with the magnitude
of the intervention effects. For the ﬁrst,
we replaced our base-case estimate for
diabetes risk reduction (55.3%) with the
estimate of 38.0% from the 10-year DPP
follow-up (35). The lower risk reduction
ﬁgure may be considered conservative be-
cause the intensive lifestyle intervention
was discontinued at the end of the
Table 2dCost of FPG testing and costs and effectiveness of a hypothetical lifestyle intervention program based on the DPP
Base-case
value
Probabilistic sensitivity analysis Univariate sensitivity
analysisDistribution assumption* Data source
Cost of FPG test ($) 5.01 Not varied Medicare fee schedule (2011)
Cost of the additional time in physician
ofﬁce visit ($) 53.20 Not varied Medicare fee schedule (2011)
Patients participating in lifestyle
intervention (%) 50 Not varied
Gans et al. (27);
Burke et al. (28)
Patients completing the lifestyle
intervention (%) 50 Triangle (0.4, 0.5, 0.6) Assumed
DPP-based lifestyle intervention (%)
Diabetes risk reduction 55.3† Normal (45, 63) DPP data† 27.5 after year 3
Hypertension risk reduction 26.0 Normal (10, 50) DPP data 19.0 Stevens et al. (42)
Hypercholesterolemia risk reduction 0.0 Not varied Assumed 22.6 Ratner et al. (43)
Cost of lifestyle intervention ($)
Year 1 1,803 Lognormal (1,803, 1,532) Herman et al. (14)
Year 2 875 Lognormal (875, 743) Herman et al. (14)
Year 3 and after 905 Lognormal (905, 769) Herman et al. (14)
Reduction of medical cost due to
intervention (year 1 to year 3) ($)‡
Women 43 Lognormal (43, 36) Herman et al. (14)
Men 135 Lognormal (135, 114) Herman et al. (14)
*Normal (a, b) = normal distribution (95% CI with a lower 2.5th percentile of a and an upper 97.5th percentile of b); lognormal (a, b) = lognormal distribution with
mean (not median) a and a lower bound of 95% conﬁdence interval b. †The 55.3% estimate of risk reduction used here is based on all DPP data through the end of July
2001 (14). A slightly higher estimate of 58%was reported earlier based onDPP data collected only throughMarch 2001 (4). ‡The reduction in the normalmedical cost
per year due to the lifestyle intervention in the ﬁrst 3 years of the intervention (zero in subsequent years).
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3-year trial period and all participants, in-
cluding those in the control group,
received a group-based lifestyle interven-
tion afterward. For the second analysis, to
account for participants’ possibly dimin-
ished adherence to the practices of the
lifestyle change intervention over time,
we assumed that the effectiveness of the in-
tervention declined by 50% after the third
year of the intervention. For the third
analysis, we varied the effectiveness of
the intervention on reducing the risk of
hypertension. For the fourth analysis, we
varied the effectiveness of the interven-
tion on reducing the risk of hypercholes-
terolemia (Table 2).
In addition, we conducted a probabi-
listic sensitivity analysis in which a set
of 85 model parameters were simulta-
neously varied based on the associated
probability in 500 iterations of the simu-
lation. The probabilities of each FPG
threshold being cost-effective, given a range
of the monetary value of QALYs gained,
were plotted to form cost-effectiveness
acceptability curves (36). Details appear
in the Supplementary Data. In addition,
we tested the statistical difference of
the ICER associated with one threshold
versus the next level using the random
sample (N = 5003 7 = 3,500) generated
from the probabilistic sensitivity analysis.
RESULTS
Base-case analysis
Table 3 shows the average lifetime cost
and QALY estimates when using different
FPG thresholds to deﬁne IFG. When
120 mg/dL was used as the initial thresh-
old for intervention, the lifetime cost was
$59,100 and achieved 10.69 QALYs. Pro-
gressively lowering the FPG threshold led
to a monotonic increase in both QALYs
and costs. Lowering the threshold from
120 to 90 mg/dL increased QALYs from
10.69 to 10.80 and increased lifetime
costs from $59,100 to $65,800. Decreas-
ing the FPG thresholddand thereby
increasing the number of people eligible
for the intervention and the health
beneﬁtdalso increased the cost per QALY
gained. Because of the monotonic rela-
tionship between the FPG threshold and
QALYs, the next higher threshold always
yielded a larger QALY than the current
one. Lowering the threshold from 120 to
115 mg/dL cost $30,100 per additional
QALY gained. The cost per QALY gained
of moving the threshold from 115 to
110 mg/dL was $32,900; from 110
to 105 mg/dL was $42,300; from 105 to
100 mg/dL was $60,700; from 100 to
95 mg/dL was $81,800; and from 95
to 90 mg/dL was $115,800.
Univariate sensitivity analyses
Table 4 shows that, regardless of model
parameters or assumptions, the ICER
consistently increased as the FPG thresh-
old was lowered. However, referring indi-
viduals to a less costly and less effective
intervention, such as PLAN4WARD, in
the ﬁrst sensitivity analysis (SA1 in Table
4) considerably reduced ICERs at all
threshold levels; these reductions were
greater at lower thresholds. The cost per
QALY gained associated with 115 mg/dL
was $21,500, compared with $30,100 in
the base-case. The cost per QALY gained
was $22,600 when lowering the thresh-
old from 115 to 110 mg/dL; $27,900
from 110 to 105 mg/dL; $40,800 from
105 to 100 mg/dL; was $71,500 from
100 to 95 mg/dL; and $96,000 from 95
to 90 mg/dL.
When the analysis was restricted to
persons aged 45–59 years (SA2), the
Table 3dLifetime cost and QALY per person and incremental cost per QALY gain under
seven FPG threshold scenarios
FPG threshold
(mg/dL) Cost (SD), $ QALYs (SD)
Incremental cost per QALY
gained (SD), $*
120 59,100 (1,500) 10.69 (0.12) d
115 59,400 (1,500) 10.70 (0.12) 30,100 (3,700)
110 60,000 (1,500) 10.72 (0.10) 32,900 (3,900)
105 60,900 (1,700) 10.74 (0.09) 42,300 (4,400)†
100 62,300 (1,800) 10.77 (0.06) 60,700 (4,200)†
95 64,100 (1,700) 10.79 (0.07) 81,800 (4,200)†
90 65,800 (1,700) 10.80 (0.07) 115,800 (3,900)†
The SDs are derived from the sample produced by the probabilistic sensitivity analysis. *Calculated by
comparing the cost and QALY of one threshold with the next most effective threshold (i.e., the threshold with
the next highest QALY). For example, the cost per QALY of the FPG threshold of 110 mg/dL is calculated by
comparing it with 115 mg/dL. Calculations were performed in full precision and costs were rounded to the
nearest $100. †The ICER of the FPG threshold is statistically different from that of the next higher threshold
(P , 0.05).
Table 4dIncremental cost per QALY ($) of FPG threshold in the univariate sensitivity analyses
FPG threshold
(mg/dL) Base case
Sensitivity analyses*
SA1 SA2 SA3 SA4 SA5 SA6 SA7 SA8 SA9 SA10
120 d d d d d d d d d d d
115 30,100 21,500 13,900 31,700 32,400 62,000 58,000 28,700 30,000 22,000 37,100
110 32,900 22,600 18,100 31,100 34,800 62,800 61,500 31,200 38,500 22,800 41,700
105 42,300 27,900 29,100 34,500 53,600 72,300 76,000 39,900 58,400 28,400 55,300
100 60,700 40,800 46,900 45,500 84,800 92,900 104,600 56,500 90,900 40,100 80,400
95 81,800 71,500 68,500 61,200 123,100 118,300 138,800 74,900 129,400 53,300 109,600
90 115,800 96,000 101,400 84,500 172,700 159,300 193,900 104,100 188,600 74,600 156,700
*SA1: used a lower-cost, lower-effectiveness lifestyle intervention based on PLAN4WARD (Promoting a Lifestyle of Activity and Nutrition for Working to Alter the
Risk of Diabetes); SA2: participants aged 45–59 years only; SA3: among persons aged 25–44, assuming that, given a same FPG value, they had a same level of the risk of
developing diabetes as persons aged 45 or older; SA4: aged $60 years only; SA5: used 10-year data from the DPP follow-up study for cost and effectiveness as-
sumptions; SA6: intervention was assumed to be 50% less effective after year 3; SA7: in addition to diabetes risk reduction, a 19% reduction in the risk of hypertension
was assumed; SA8: in addition to diabetes risk reduction, a 22.6% reduction of the risk of hypercholesterolemia was assumed; SA9: cost andQALYwere discounted at
0% per year; SA10: cost and QALY were discounted at 5% per year. Calculations were performed in full precision and costs were rounded to the nearest $100.
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ICERs were lower at all FPG thresholds,
ranging from $13,900 to $101,400 per
QALY gained. For persons aged 25–44
(SA3), the ICERs for most of the thresh-
olds evaluated were also lower than those
in persons aged 45 or older. In compari-
son, the ICER for individuals aged $60
years were higher, ranging from $32,400
to $172,700 per QALY gained (SA4). Us-
ing data from the 10-year DPP risk reduc-
tion estimate (SA5) resulted in higher
ICERs, as did assuming a long-term dimin-
ishing effect of the intervention (SA6).
However, assuming that lifestyle interven-
tion also reduced the risk of developing
hypertension (SA7) or hypercholesterolemia
(SA8) resulted in lower ICERs.
Probabilistic sensitivity analysis
Figure 1 shows the cost effectiveness
acceptability curves of seven FPG thresh-
olds. Each curve represents the probability
that the given threshold is cost-effective
by the monetary value of a QALY, or will-
ingness to pay. One FPG threshold would
be more likely to be cost-effective if the
willingness to pay for QALY gain is higher.
For instance, in a scenario in which the
monetary value of $50,000 per QALY (a
conventional benchmark ﬁgure for a soci-
ety’s willingness to pay [37]) is assigned,
the probability of the 105-mg/dL IFG
threshold will be cost-effective was 0.92.
The probability would increase to 0.99 if
the value of a QALY was increased to
$60,000. However, the probability that
an IFG threshold of 100 mg/dL is cost ef-
fective is 0.29 and 0.65 at the willingness-
to-pay benchmarks of the $50,000 and
$60,000 per QALY, respectively. Each
FPG threshold was statistically signiﬁ-
cantly different from its next higher thresh-
old, except the level of 110 mg/dL. Details
about the results of the probabilistic sensi-
tivity analysis appear in section VII of the
Supplementary Data.
CONCLUSIONSdFPG tests have
been increasingly used to identify indi-
viduals at high risk of developing type 2
diabetes and refer them for diabetes pre-
vention interventions (38). The selection
of the threshold of the FPG test deter-
mines the target population for preven-
tive intervention and thus ultimately
affects the efﬁciency of the interventions.
The economic implications need to be
well understood so scarce health care re-
sources can be used in an efﬁcient manner.
In this study we examined the cost-
effectiveness of seven possible FPG test
thresholds when they were used for refer-
ral to a diabetes prevention intervention.
We found that as the FPG threshold was
lowered the population-level health ben-
eﬁt increased but cost-effectiveness was
reduced.
Our study results suggest that the
selection of the FPG threshold may ulti-
mately depend on the health care resources
that are available for diabetes prevention
or the willingness to pay to prevent di-
abetes. A lower IFG threshold might be
preferred if more resources are available or
the willingness to pay for preventing di-
abetes is higher. Using $50,000 per QALY
as a benchmark for acceptability (37), we
are quite certain (with more that 90% cer-
tainty) that diabetes prevention would be
cost-effective if we used an FPG level of
105 mg/dL as the threshold to identify a
high-risk state. However, if a higher will-
ingness to pay per QALYwere acceptable, a
threshold that is lower than 105 mg/dL is
preferred.
Furthermore, our ﬁndings suggest
that a lower threshold might be preferred
if the cost of the diabetes prevention in-
tervention could be reduced. In our sen-
sitivity analysis, under a scenario in which
a less costly but less effective intervention
was used, cost-effectiveness was improved
at all threshold levels. For instance, the
ICER associated with the threshold of 100
mg/dL decreased from $60,700 per QALY
in the base-case to $40,800 per QALY
when the less costly and less effective in-
tervention was used. This indicates that by
using the less expensive intervention the
FPG threshold could be lowered from 105
to 100 mg/dL, even when the willingness
to pay benchmark remained at the same
level of $50,000 per QALY. Because the
cost of the intervention affects the cost-
effectiveness of the FPG threshold, it
ultimately affects the selection of an eco-
nomically preferred threshold of the FPG
test for diabetes prevention.
Our study demonstrates a deteriorat-
ing cost-effectiveness associated with the
decreasing FPG threshold and provides
a valuable health economics perspective
into the debate over the selection of the
optimal FPG threshold. However, our
study did not aim to determine the de-
ﬁnitive value of a universally optimal
threshold because selecting such a thresh-
old may depend on many factors. In par-
ticular, the cost-effectiveness of a speciﬁed
FPG threshold is likely to change by age:
the risk of type 2 diabetes indicated by the
value may vary depending on age (39,40).
To understand how such differences in the
population might affect the choice of a
threshold, we estimated the ICERs at
each FPG threshold by age group. We
Figure 1dCost-effectiveness acceptability curves associated with alternative FPG thresholds.
Note that the FPG threshold of 120 mg/dL served as the reference threshold for 115 mg/dL. For
each of the other FPG thresholds, the next higher threshold served as the reference threshold. For
instance, the comparison threshold for FPG 110 mg/dL was 115 mg/dL. See Table 3 for more
details.
3996 DIABETES CARE, VOLUME 36, DECEMBER 2013 care.diabetesjournals.org
Economic FPG thresholds to identify high risk
found lower cost-effectiveness ratios asso-
ciated with all FPG thresholds in those
aged 45–64 years and younger than 45
than in those aged $65 years. This is pri-
marily because of the longer life expectancy
of the younger populations. Preventing
more cases of type 2 diabetes and possibly
other risk factors over that time creates a
higher likelihood of recouping the cost of
the intervention via reduced treatment and
complication costs, even though the inter-
vention ismore effective in the older group.
Limitations
Our study has several limitations. First,
our analysis is based on a single measure
of FPG. Since FPG can vary from day to
day, multiple measures might give a bet-
ter deﬁnition of IFG. Second, FPG is one
of several markers that can be used to
identify people at high risk for developing
type 2 diabetes. Recent ADA guidelines
also recommended A1C as a test to
identify people at high risk (6). Other var-
iables such as sex, race/ethnicity, family
history, and body weight may affect an
individual’s future risk of type 2 diabetes
(39–41). Future studies should examine
the cost-effectiveness of alternative
thresholds of FPG testing, stratiﬁed by
other risk factors, when data on diabetes
incidences are available for those stratiﬁed
subpopulations. Third, our simulation
model was developed based on data col-
lected from multiple sources and thus was
inevitably subject to the accuracy of the data
sources and the assumptions used by the
researchers in the source studies.
Conclusion
When FPG testing is used to identify a
target population for type 2 diabetes pre-
vention, selecting a lower FPG threshold
leads to a greater gain in overall health
beneﬁt but also to a deteriorated cost-
effectiveness. The selection of an appropri-
ate FPG threshold for any given population
ultimately depends on the resources avail-
able or the willingness to pay for diabetes
prevention. Using the conventional bench-
mark of $50,000 per QALY, a threshold of
105 mg/dL or higher is highly likely to be
cost effective. Furthermore, a lower FPG
threshold is preferred if the cost of the
intervention can be lowered without com-
promising too much effectiveness.
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